Valganciclovir (Valcyte)

DRUG2 trials

Sponsors

Karolinska Institutet, National Taiwan University Hospital

Conditions

Antiviral ProphylaxisCytomegalovirus InfectionEBV InfectionGlioblastoma MultiformeKidney Transplantation, Cytomegalovirus Infections

Unknown Phase

Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

CompletedNCT00400322

Karolinska InstitutetCytomegalovirus Infection, Glioblastoma Multiforme

Start: 2006-08-31End: 2008-06-30Updated: 2021-03-01

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

RecruitingNCT07294547

National Taiwan University HospitalAntiviral Prophylaxis, EBV Infection, Kidney Transplantation, Cytomegalovirus Infections

Start: 2025-11-27End: 2030-12-31Target: 80Updated: 2025-12-19